Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Citius Pharmaceuticals, Inc. (CTXR)
|
Add to portfolio |
|
|
|
| Price: |
$1.69
| | Metrics |
| OS: |
158.9
|
M
| |
|
|
| Market cap: |
$268
|
M
| |
|
|
|
Net cash:
|
$33.3
|
M
| |
$0.21
|
per share
|
|
EV:
|
$235
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Sep-30-22 | Sep-30-21 | Sep-30-20 | Sep-30-19 | Sep-30-18 | Sep-30-17 | Sep-30-16 | Sep-30-15 |
| Revenues | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 |
| Revenue growth | 0.0% | 0.0% | 0.0% | 20.0% | 50.0% | -655.9% | | |
| Cost of goods sold | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -400.3% | |
| Research and development | 17.7 | 12.2 | 8.8 | 8.6 | 6.6 | 2.9 | 2.9 | 1.8 |
| General and administrative | 11.8 | 9.8 | 8.1 | 6.3 | 6.4 | 6.1 | 3.8 | 0.9 |
| EBIT | -33.3 | -23.5 | -17.7 | -15.6 | -13.8 | -10.0 | -7.4 | -3.2 |
| EBIT margin | -37017.8% | -26146.5% | -19678.5% | -17331.5% | -18385.5% | -19972.6% | 82825.1% | |
| Pre-tax income | -33.1 | -23.1 | -17.5 | -15.6 | -12.5 | -10.4 | -8.3 | -2.9 |
| Income taxes | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -33.6 | -24.5 | -17.5 | -15.6 | -12.5 | -10.4 | -8.3 | -2.9 |
| Net margin | -37378.5% | -27228.1% | -19497.9% | -17291.3% | -16715.5% | -20769.9% | 92235.9% | |
| |
| Diluted EPS | ($0.23) | ($0.23) | ($0.45) | ($0.77) | ($1.17) | ($1.89) | ($2.29) | ($1.37) |
| Shares outstanding (diluted) | 146.1 | 108.6 | 39.2 | 20.2 | 10.7 | 5.5 | 3.6 | 2.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|